XML 143 R135.htm IDEA: XBRL DOCUMENT
v3.25.3

Share-Based Payments - Model Inputs for STI Performance Rights Granted (Detail) - Short Term Incentives Performance Rights [member] - $ / shares |  |  |  |  |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Dec. 05, 2024 | [3] | Nov. 22, 2024 | [3] | Jan. 31, 2024 | [3] | Oct. 24, 2023 | Nov. 23, 2022 | Jun. 30, 2024 | Jun. 30, 2023
Disclosure of other equity instruments [line items] |  |  |  |  |  |  |  |  |
Share price at grant date |  |  |  | $ 0.32 | $ 0.31 | $ 0.295 | [1] | $ 0.315 | [2]
Expected price volatility of the Company's shares |  |  |  | 56.00% | 75.00% | 62.00% | [1] | 75.00% | [2]
Expected dividend yield |  |  |  | 0.00% | 0.00% | 0.00% | [1] | 0.00% | [2]
Risk-free interest rate |  |  |  | 4.30% | 3.40% | 4.11% | [1] | 3.94% | [2]
Executive Incentive Plan [Member] |  |  |  |  |  |  |  |  |
Disclosure of other equity instruments [line items] |  |  |  |  |  |  |  |  |
Share price at grant date | $ 0.31 | $ 0.305 | $ 0.35 |  |  | $ 0.295 | [3] | $ 0.275 | [4]
Expected price volatility of the Company's shares | 63.00% | 63.00% | 58.00% |  |  | 62.00% | [3] | 60.00% | [4]
Expected dividend yield |  |  |  |  |  |  | [3] |  | [4]
Risk-free interest rate | 3.88% | 4.20% | 3.68% |  |  | 4.19% | [3] | 3.40% | [4]
[1] | Director performance rights granted during the year ended June 30, 2024 have not met the definition of grant date under AASB 2(IFRS 2) - Share Based payments. Accordingly, the share-based expense recognized was using an estimate of the grant date fair value at June 30, 2024. The value will be re- assessed at the next reporting date as the grant date will be the 2024 AGM date.
[2] | Director performance rights granted during the year ended June 30, 2023 have not met the definition of grant date under AASB 2 (IFRS 2) - Share Based payments. Accordingly, the share-based expense recognised was using an estimate of the grant date fair value at June 30, 2023. The value will be re- assessed at the next reporting date as the grant date will be the 2023 AGM date.
[3] | 3,147,952 performance rights due to vest on October 1, 2024, 3,147,952 performance rights due to vest on October 1, 2025 and 447,952 performance rights due to vest on October 1, 2026 have not met the definition of grant date under AASB 2 (IFRS 2)- Share Based payments. Accordingly, the share-based expense recognised was using an estimate of the grant date fair value at June 30, 2024. The value will be re-assessed at each reporting date until grant date has been identified. For all tranches, the vesting conditions consist of service-based vesting conditions subject to certain defined corporate Key Performance Indicators (KPIs). The performance rights will expire, if not exercised, five years from the date of issue. There are no outstanding options under EIP at the beginning of the financial year 2024 and no option was granted during the year ended June 30, 2024.
[4] | 2,700,000 performance rights due to vest on October 1, 2024 and 2,700,000 performance rights due to vest on October 1, 2025 have not met the definition of grant date under AASB 2(IFRS2) - Share Based payments. Accordingly, the share-based expense recognised was using an estimate of the grant date fair value at June 30, 2023. The value will be re-assessed at each reporting date until grant date has been identified. For all tranches, the vesting conditions consist of service-based vesting conditions subject to certain defined corporate Key Performance Indicators (KPIs). The performance rights will expire, if not exercised, five years from the date of issue. There are no outstanding options under EIP at the beginning of the fiscal year 2023 and no option was granted during the year ended June 30, 2023.

X
- Definition Line items of other equity instruments. + References No definition available. + Details
Name: | immp_DisclosureOfOtherEquityInstrumentsLineItems
Namespace Prefix: | immp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected dividend as percentage, other equity instruments granted. + References No definition available. + Details
Name: | immp_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
Namespace Prefix: | immp_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected volatility, other equity instruments granted. + References No definition available. + Details
Name: | immp_ExpectedVolatilityOtherEquityInstrumentsGranted
Namespace Prefix: | immp_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Risk free interest rate, other equity instruments granted. + References No definition available. + Details
Name: | immp_RiskFreeInterestRateOtherEquityInstrumentsGranted
Namespace Prefix: | immp_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average share price of other equity instruments granted. + References No definition available. + Details
Name: | immp_WeightedAverageSharePriceOtherEquityInstrumentsGranted
Namespace Prefix: | immp_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=immp_ShortTermIncentivesPerformanceRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | immp_PlanName1Axis=immp_ExecutiveIncentivePlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |